The British Journal of Psychiatry (2009) 194: 181-182. doi: 10.1192/bjp.bp.107.047951
© 2009 The Royal College of Psychiatrists
Duration of untreated prodromal symptoms and 12-month functional outcome of individuals at risk of psychosis
P. Fusar-Poli, MD
OASIS, South London and Maudsley NHS Trust, and Institute of Psychiatry,
King's College London, UK
A. Meneghelli, MD
Programma 2000, A.O. Ospedale Niguarda Ca' Granda, Milan, Italy
L. Valmaggia, PhD and
P. Allen, PhD
OASIS, South London and Maudsley NHS Trust, and Institute of Psychiatry,
King's College London, UK
F. Galvan, MD
Programma 2000, A.O. Ospedale Niguarda Ca' Granda, Milan, Italy
P. McGuire, PhD
OASIS, South London and Maudsley NHS Trust, and Institute of Psychiatry,
King's College London, UK
A. Cocchi, MD
Programma 2000, A.O. Ospedale Niguarda Ca' Granda, Milan, Italy
Correspondence:
P. Fusar-Poli, Neuroimaging Section, PO67, Department of Psychological
Medicine, Institute of Psychiatry, De Crespigny Park, London SE5 8AF, UK.
Email:
p.fusar{at}libero.it
Declaration of interest
None.

ABSTRACT
Individuals seeking help from prodromal services may have been
experiencing
attenuated psychotic features and psychosocial
impairments for a long period
prior to referral. The effect
of an extended duration of these untreated `at
risk' symptoms
on patients' long-term functional outcome was assessed in a
12-month longitudinal observational study (
n=49). A longer
duration
of untreated `at risk' symptoms was correlated with
a reduced improvement in
Global Assessment of Functioning scores
after 12 months (β=–0.375,
P=0.008). This effect
was independent of age and gender and may have
implications
for the improvement of treatment strategies in pre-psychotic
phases.

INTRODUCTION
Recent systematic reviews and meta-analyses indicate that there
is a
consistent relationship between the duration of untreated
psychosis and
psychosocial outcome independent of other
factors.
1,2
However, many symptoms and a great deal of functional and social
disability
develop during the prodromal phase preceding the
onset of first-episode
psychosis.
3,4
Neurobiological and neurocognitive
changes may also occur during this
pre-psychotic
period.
5 Although
growing evidence suggests that a longer prodromal
phase of psychosis is
associated with poorer
outcomes,
6 such
observations are based on retrospective studies and are clinically
useless as
preventive strategies. Psychopathological instruments
are now available that
allow the identification – in
a longitudinal perspective – of
individuals with `at
risk' symptoms (for a definition of `at risk' symptoms
see
Method). As individuals who are at clinical risk for psychosis
may or may
not develop the
disorder,
3 the
impact of the duration
of their presenting symptoms on long-term functional
outcome
is mostly unknown.

Method
The setting of this longitudinal observational study was the
out-patient
service `Programma 2000' based in Milan, Italy.
This early-intervention
clinical service provides 5 years of
psychotherapy, psychoeducational and
psychopharmacological
interventions for individuals at clinical risk of
psychosis.
All patients at risk for psychosis assessed at the clinic between
2000 and 2006 were enrolled and followed up over a 1-year period.
The
inclusion criteria for being considered at clinical risk
for psychosis have
been developed by the Early Detection and
Intervention programme of the German
Research Network on
Schizophrenia.
7
Clinical assessment was performed using the Early Recognition
Inventory
(ERIraos),
8,9
which defines the prodromal state
as one of the following: (a) presenting with
certain self-experienced
cognitive thought and perception deficits (`basic
symptoms'
according to Klosterkotter
et
al4); and/or
(b) demonstrating
a clinical decline in functioning in combination with other
well-established risk
factors.
3 Exclusion
criteria were:
being aged <18 and >36, presenting with any medical
conditions
or any previous diagnosis of a schizophrenic, schizophreniform,
schizoaffective, delusional, bipolar or brief psychotic disorder
according to
DSM–IV.
7
Socio-demographic characteristics
were recorded via an unstandardised
questionnaire and clinical
assessment was conducted by two psychiatrists.
Psychopathological
characteristics of the sample were collected by using the
Brief
Psychiatric Rating Scale
(BPRS)
10,
ERIraos,
8 Global
Assessment
of Functioning
(GAF)
11 and Health
of the Nation Scale
(HoNOS)
12
instruments at baseline (first contact with the prodromal service),
6 and 12
months. Duration of untreated `at risk' symptoms was
operationally defined as
the first onset of specific basic
symptoms as assessed using ERIraos: thought
interference; thought
perseveration; thought pressure; thought blockage;
disturbances
of receptive language; decreased ability to discriminate between
ideas and perception and between fantasy and true memories;
unstable ideas of
reference (subject-centrism); derealisation;
visual perception disturbance;
and acoustic perception
disturbance.
7 All
participants gave informed consent to be part of the study.
Descriptive statistics (means and standard deviations for continuous
variables and relative frequencies for categorical variables) were computed.
Mean and 95% confidence intervals (CIs) of BPRS, GAF, ERIraos and HoNOS at
baseline, 6 months and 12 months were also calculated. Repeated-measures ANOVA
was used to assess changes in BPRS, GAF, ERIraos and HoNOS scores over the
three time points. Pearson's correlation coefficients (R) were computed to
estimate the correlation between GAF change (GAF after 12 months – GAF
at baseline) and baseline characteristics. The association between the primary
outcome (GAF change) and predictors was assessed by a general linear
regression analysis, after checking for collinearity. The choice between
collinear variables was based on clinical considerations. Variation due to the
association model was estimated by the R2 statistic. SPSS V.15 for
Windows was used for all statistical analyses. Two-tailed P-values
<0.01 were considered statistically significant.

Results
Overall, 49 individuals (65% males) participated in the study
(9 of the
original sample of 58 participants did not complete
the follow-up
assessments). There were no significant socio-demographic
differences between
male and female participants (
t-tests,
P>0.05).
Socio-demographic data and scores on the BPRS,
GAF, HoNOS and ERIraos at
baseline, 6-month and 12-month follow-up
are reported in online Table DS1.
Repeated-measures ANOVA of
clinical ratings across time points (baseline, 6
months and
12 months) showed a significant improvement in GAF
(
F=48.86,
d.f.=2,
P<0.001), HoNOS (
F=20.85,
d.f.=2,
P<0.001), ERIraos
(
F=34.82, d.f.=2,
P<0.001) and BPRS (
F=31.11, d.f.=2,
P<0.001)
scores over time.
A significant negative correlation between GAF score change
over 12 months
and duration of the untreated `at risk' symptoms
at baseline was observed
(
r=–0.494,
P=0.001;
Fig. 1),
but the correlations
between GAF change and baseline BPRS,
ERIraos, HoNOS and age were
non-significant (
r=–0.008,
P=0.960;
r=–0.065,
P=0.683;
r=–0.012,
P=0.938;
r=–0.030,
P=0.849 respectively).
We then built the regression model entering different factors (online Table
DS2) and tested it, confirming that the duration of untreated `at risk'
symptoms was negatively associated with change in GAF scores (standardised
β coefficient=–0.375, P=0.008). There was a moderate,
albeit non-significant (P>0.01), association between GAF outcomes
at 12 months and being a graduate (standardised β=0.367,
P=0.012) and being employed (standardised β=0.300,
P=0.030). The model remained significant after adjusting for age,
gender and symptoms (BPRS at 12 months – BPRS at baseline) and was able
to explain 51% of the variance.

Discussion
The low predictive value and the high rate of false positives
associated
with the available assessment instruments for people
at risk of psychosis have
raised methodological criticisms
and several ethical concerns regarding
interventions in pre-psychotic
phases.
13 However,
in line with evidence showing that preventive
intervention in psychosis is
feasible and effective, in our
sample the global functioning of individuals at
clinical risk
for psychosis improved over the 12-month follow-up, presumably
because of treatment. Despite these encouraging findings, young
people seeking
help from prodromal services may have been experiencing
attenuated psychotic
symptoms and psychosocial impairments
for a long period before referral. In
fact, we found that,
on average, the first contact with prodromal services is
preceded
by a period of more than 2 years in which individuals are
experiencing
subtle and attenuated `at risk' symptoms. In addition, we found
that the duration of these untreated `at risk' symptoms has
a detrimental
effect on long-term global functioning
(
Fig. 1).
Previous
cross-sectional studies have confirmed that individuals
at risk for
schizophrenia have significant functional
deficits
14 that
precede overt symptom
formation.
15
Duration of untreated `at risk' symptoms may be a potentially modifiable
prognostic factor through a nationwide development of prodromal services and a
rapid referral of `at risk' individuals. Although our study is limited by a
small sample size and psychopathological heterogeneity across individuals at
risk for psychosis, our findings support a very early detection of `at risk'
symptoms. Early diagnosis and early intervention services based in primary
care and in the wider community (e.g. school counsellors, job centres and
community youth centres) could improve long-term functioning of at-risk
individuals independent of clinical outcome. A selective focus on the general
functioning of the patient instead of their symptomatic profile seems to be
one of the most promising end-point measures in future preventive
interventions. Understanding the mechanism by which the duration of untreated
`at risk' symptoms interacts with environmental and genetic factors leading to
transition to psychosis will also shed light on the pathophysiology of the
prodromal phases of psychoses and may help improve treatment strategies.

REFERENCES
1 - Perkins DO, Gu H, Boteva K, Lieberman JA (2005) Relationship
between duration of untreated psychosis and outcome in first-episode
schizophrenia: a critical review and meta-analysis. Am J
Psychiatry 2005; 162: 1785
-804.[Abstract/Free Full Text]
2 - Norman RMG, Lewis SW, Marshall M. Duration of untreated psychosis
and its relationship to clinical outcome. Br J
Psychiatry 2005; 187
(suppl 48): s19-23.[Abstract/Free Full Text]
3 - Yung AR, Phillips LJ, McGorry PD, McFarlane CA, Francey S, Harrigan
S, et al. Prediction of psychosis. Br J Psychiatry 1998; 172 (suppl. 33): s14
-20.
4 - Klosterkötter J, Hellmich M, Steinmeyer EM, Schultze-Lutter F.
Diagnosing schizophrenia in the initial prodromal phase. Arch Gen
Psychiatry 2001; 58: 158
-64.[Abstract/Free Full Text]
5 - Fusar-Poli P, Perez J, Broome M, Borgwardt S, Placentino A,
Caverzasi E, et al. Neurofunctional correlates of vulnerability to psychosis:
a systematic review and meta-analysis. Neurosci Biobehav
Rev 2007; 31: 465
-84.[CrossRef][Medline]
6 - Keshavan MS, Haas G, Miewald J, Montrose DM, Reddy R, Schooler NR,
et al. Prolonged untreated illness duration from prodromal onset predicts
outcome in first episode psychoses. Schizophr Bull 2003; 29: 757
-69.[Abstract/Free Full Text]
7 - Bechdolf A, Ruhrmann S, Wagner M, Kühn KU, Janssen B,
Bottlender R, et al. Interventions in the initial prodromal states of
psychosis in Germany: concept and recruitment. Br J
Psychiatry 2005; 187
(suppl 48): s45-8.[Abstract/Free Full Text]
8 - Maurer K, Horrmann F, Schmidt M, Trendler G, Hafner H. The early
recognition inventory: structure, reliability and initial results.
Schizophr Res 2004;
67 (suppl): 34
.
9 - Häfner H, Maurer K, Ruhrmann S, Bechdolf A, Klosterkötter
J, Wagner M, et al. Are early detection and secondary prevention feasible?
Facts and visions. Eur Arch Psychiatry Clin Neurosci 2004; 254: 117
-28.[CrossRef][Medline]
10 - Overall JE, Gorham DR. The Brief Psychiatric Rating Scale.
Psychol Rep 1962;
10: 799
-812.
11 - American Psychiatric Association. Multiaxial assessment. In
Diagnostic and Statistical Manual of Mental Disorders (4th edn,
text revised) (DSM–IV–TR). APA, 2002
.
12 - Wing JK, Beevor AS, Curtis RH, Park SB, Hadden S, Burns A. Health
of the Nation Outcome Scales (HoNOS). Research and development. Br
J Psychiatry 1998;
172: 11-8.[Abstract/Free Full Text]
13 - Cornblatt BA, Auther AM, Niendam T, Smith CW, Zinberg J, Bearden
CE, et al. Preliminary findings for two new measures of social and role
functioning in the prodromal phase of schizophrenia. Schizophr
Bull 2007; 33: 688
-702.[Abstract/Free Full Text]
14 - Ballon JS, Kaur T, Marks II, Cadenhead KS. Social functioning in
young people at risk for schizophrenia. Pscyhiatry Res 2007; 151: 29
-35.[CrossRef]
15 - Melle I, Haahr U, Friis S, Hustoft K, Johannessen JO, Larsen TK, et
al. Reducing the duration of untreated first-episode psychosis: effects on
baseline social functioning and quality of life. Acta Psychiatr
Scand 2005; 112: 469
-73.[CrossRef][Medline]
Received for publication November 20, 2007.
Revision received September 5, 2008.
Accepted for publication September 8, 2008.
Related articles in BJP:
- From the Editor's desk
- Peter Tyrer
BJP 2009 194: 198.
[Full Text]
This article has been cited by other articles:

|
 |

|
 |
 
P. Tyrer
From the Editor's desk
The British Journal of Psychiatry,
January 1, 2010;
196(1):
86 - 86.
[Full Text]
[PDF]
|
 |
|